Therapeutic silencing of an endogenous gene by siRNA cream in an arthritis model mouse

Gene Therapy

Volumn 16, Issue 8, 2009, Pages 982-989

  Takanashi, M ^a   Oikawa, K ^a   Sudo, K ^a   Tanaka, M ^a   Fujita, K ^a   Ishikawa, A ^a   Nakae, S ^b   Kaspar, R L ^c   Matsuzaki, M ^d   Kudo, M ^a   Kuroda, M ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TransDerm Inc   (United States)

^d Miracure Inc   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 2; GENECREAM; OSTEOPONTIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE INJURY; CELL MIGRATION; CONTROLLED STUDY; CREAM; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG PENETRATION; GENE SILENCING; GENE TARGETING; GENE THERAPY; HISTOCHEMISTRY; MACROPHAGE; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, TOPICAL; ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; FEMALE; GENE EXPRESSION REGULATION; GENE TARGETING; GENE THERAPY; GENE TRANSFER TECHNIQUES; MICE; MICE, INBRED BALB C; OINTMENTS; OSTEOPONTIN; RNA INTERFERENCE; RNA, SMALL INTERFERING; SKIN; SKIN ABSORPTION;

EID: 69249215187     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2009.66     Document Type: Article

References (45)

1. Dykxhoorn DM, Lieberman J. Knocking down disease with siRNAs. Cell 2006; 126: 231-235.
2. McCaffrey AP, Meuse L, Pham TT, Conklin DS, Hannon GJ, Kay MA. RNA interference in adult mice. Nature 2002; 418: 38-39.
3. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004; 432: 173-178.
4. Takeshita F, Minakuchi Y, Nagahara S, Honma K, Sasaki H, Hirai K et al. Efficient delivery of small interfering RNA to bonemetastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA 2005; 102: 12177-12182.
5. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN et al. RNAi-mediated gene silencing in non-human primates. Nature 2006; 441: 111-114.
6. Kumar P, Wu H, McBride JL, Jung KE, Kim MH, Davidson BL et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007; 448: 39-43.
7. Zhang Q, Zhang ZF, Rao JY, Sato JD, Brown J, Messadi DV et al. Treatment with siRNA and antisense oligonucleotides targeted to HIF-1alpha induced apoptosis in human tongue squamous cell carcinomas. Int J Cancer 2004; 111: 849-857.
8. Bitko V, Musiyenko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005; 11: 50-55.
9. Zhang X, Shan P, Jiang D, Noble PW, Abraham NG, Kappas A et al. Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis. J Biol Chem 2004; 279: 10677-10684.
10. Reich SJ, Fosnot J, Kuroki A, Tang W, Yang X, Maguire AM et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003; 9: 210-216.
11. Pfutzner W, Vogel JC. Advances in skin gene therapy. Expert Opin Investig Drugs 2000; 9: 2069-2083.
12. Khavari PA, Rollman O, Vahlquist A. Cutaneous gene transfer for skin and systemic diseases. J Intern Med 2002; 252: 1-10.
13. Hengge UR, Walker PS, Vogel JC. Expression of naked DNA in human, pig, and mouse skin. J Clin Invest 1996; 97: 2911-2916.
14. Vogel JC. A direct in vivo approach for skin gene therapy. Proc Assoc Am Phys 1999; 111: 190-197.
15. Raghavachari N, Fahl WE. Targeted gene delivery to skin cells in vivo a comparative study of liposomes and polymers as delivery vehicles. J Pharm Sci 2002; 91: 615-622.
16. Prud'homme GJ, Glinka Y, Khan AS, Draghia-Akli R. Electroporation- enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases. Curr Gene Ther 2006; 6: 243-273.
17. Takei Y, Nemoto T, Mu P, Fujishima T, Ishimoto T, Hayakawa Y et al. In vivo silencing of a molecular target by short interfering RNA electroporation: Tumor vascularization correlates to delivery efficiency. Mol Cancer Ther 2008; 7: 211-221.
18. Patarca R, Freeman GJ, Singh RP, Wei FY, Durfee T, Blattner F et al Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection. J Exp Med 1989; 170: 145-161.
19. Weber GF, Cantor H. The immunology of Eta-1/osteopontin. Cytokine Growth Factor Rev 1996; 7: 241-248.
20. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S et al. Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity. Science 2000; 287: 860-864.
21. O'Regan AW, Nau GJ, Chupp GL, Berman JS. Osteopontin (Eta-1) in cell-mediated immunity: Teaching an old dog new tricks. Immunol Today 2000; 21: 475-478.
22. Yumoto K, Ishijima M, Rittling SR, Tsuji K, Tsuchiya Y, Kon S et al Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc Natl Acad Sci USA 2002; 99: 4556-4561.
23. Xu G, Nie H, Li N, Zheng W, Zhang D, Feng G et al. Role of osteopontin in amplification and perpetuation of rheumatoid synovitis. J Clin Invest 2005; 115: 1060-1067.
24. Yamamoto N, Sakai F, Kon S, Morimoto J, Kimura C, Yamazaki H et al Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis. J Clin Invest 2003; 112 181-188.
25. Xanthou G, Alissafi T, Semitekolou M, Simoes DC, Economidou E, Gaga M et al. Osteopontin has a crucial role in allergic airway disease through regulation of dendritic cell subsets. Nat Med 2007; 13 570-578.
26. Hopewell JW. The skin: Its structure and response to ionizing radiation. Int J Radiat Biol 1990; 57: 751-773.
27. Valoczi A, Hornyik C, Varga N, Burgyan J, Kauppinen S, Havelda Z. Sensitive and specific detection of microRNAs by northern blot analysis using LNA-modified oligonucleotide probes. Nucleic Acids Res 2004; 32: E175.
28. Wienholds E, Kloosterman WP, Miska E, Alvarez-Saavedra E, Berezikov E, de Bruijn E et al. MicroRNA expression in zebrafish embryonic development. Science 2005; 309: 310-311.
29. Wang Q, Ilves H, Chu P, Contag CH, Leake D, Johnston BH et al. Delivery and inhibition of reporter genes by small interfering RNAs in a mouse skin model. J Invest Dermatol 2007; 127: 2577-2584.
30. Thanik VD, Greives MR, Lerman OZ, Seiser N, Dec W, Chang CC et al. Topical matrix-based siRNA silences local gene expression in a murine wound model. Gene Therapy 2007; 14: 1305-1308.
31. Shanahan JC, St Clair W. Tumor necrosis factor-alpha blockade: A novel therapy for rheumatic disease. Clin Immunol 2002; 103: 231-242.
32. Park JY, Pillinger MH. Interleukin-6 in the pathogenesis of rheumatoid arthritis. Bull NYU Hos Jt Dis 2007; 65(Suppl 1): S4-S10.
33. Koenders MI, Joosten LA, van den Berg WB. Potential new targets in arthritis therapy: Interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis. Ann Rheum Dis 2006; 65(Suppl 3): Iii29-iii33.
34. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:FC fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-259.
35. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-1602.
36. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
37. Nishimoto N, Yoshizaki K, Maeda K, Kuritani T, Deguchi H, Sato B et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol 2003; 30: 1426-1435.
38. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50: 1761-1769.
39. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthritis Rheum 2003; 48: 2122-2127.
40. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50: 1740-1751.
41. Mader R, Keystone E. Optimizing treatment with biologics. J Rheumatol Suppl 2007; 80: 16-24.
42. van Ede AE, Laan RF, Blom HJ, De Abreu RA, van de Putte LB. Methotrexate in rheumatoid arthritis: An update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum 1998; 27: 277-292.
43. Imokawa S, Colby TV, Leslie KO, Helmers RA. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J 2000; 15: 373-381.
44. Saito Y, Kon S, Fujiwara Y, Nakayama Y, Kurotaki D, Fukuda N et al Osteopontin small interfering RNA protects mice from fulminant hepatitis. Hum Gene Ther 2007; 18: 1205-1214.
45. Terato K, Hasty KA, Reife RA, Cremer MA, Kang AH, Stuart JM. Induction of arthritis with monoclonal antibodies to collagen. J Immunol 1992; 148: 2103-2108.